Uncovering Key Critical Safety Requirements for Clinical & Post-Authorisation Measures for mRNA Vaccines & Therapeutics
Time: 12:45 pm
day: Day 2 Track 2 PM
Details:
- Leveraging case study examples on safety and pharmacovigilance for mRNA-based vaccines for COVID-19 and RSV
- Establishing regulatory measures for emerging safety concerns and restrictions, with patient and healthcare professionals in mind
- Shaping a risk management plan for pharmacovigilance, post authorization studies, and risk minimization measures for future mRNA vaccines and therapeutics
